| INTRODUCTION
Prophylaxis with replacement factor VIII (FVIII) is the recommended standard of care for persons with severe haemophilia A. 1, 2 Increasingly, in the developed world, individualized tailoring of prophylaxis regimens, based on considerations such as each patient's activity level, bleeding phenotype, pharmacokinetics (PKs), personal goals and preferences, is becoming the preferred treatment approach. 3, 4 The advent of extended half-life (EHL) recombinant FVIII products, bioengineered to have a longer half-life than standard recombinant proteins, represents an important expansion of treatment options to be considered as part of individualized haemophilia care. 5, 6 Extension of half-life allows for the possibility of increasing trough levels without increasing infusion frequency, or maintaining trough levels while reducing infusion frequency. Depending on the patient, either of these strategies could be employed to improve outcomes by reducing the burden of therapy, potentially increasing adherence; or by providing greater protection against bleeding and associated bleed-related sequelae.
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Particularly in rare diseases such as haemophilia, real-world data can help to inform routine clinical decision-making by providing information on treatment effectiveness and safety under real-world conditions, and in patients who are typically ineligible for clinical studies (eg, patients with a history of an inhibitor). 8 Real-world evidence can complement clinical trial data by providing insights into how physicians and patients make treatment choices and by documenting the dosing regimens used in the clinical setting. Specifically with regard to EHL factor products, real-world data can help to determine whether or not their putative benefits, such as improved adherence and enhanced quality of life, are actually realized. 
| MATERIALS AND METHODS
A retrospective chart (medical record) review study at three paediatric haemophilia treatment centres (HTCs) in Ohio, USA was per- Variables relating to patient and clinical characteristics, treatment regimens, PK assessments, bleeding events and patient satisfaction were analysed descriptively, using frequencies and percentages where appropriate.
The study was conducted in compliance with the Declaration of Helsinki, and study materials were reviewed and approved by the institutional review boards of each participating HTC.
| RESULTS

| Patient characteristics
Across the three participating centres, a total of 15 male patients who began treatment with Adynovate within the specified timeframe were identified ( and reduce joint pain or improve joint function (2 patients) ( Figure 1 ).
In 10 of 15 cases, the discussion about switching was initiated by the patient or by parental request.
| Dosing regimens and factor consumption
At the time of the chart review, or last clinic contact if subsequent to the chart review, patients had received Adynovate for a median of 9 months (range 1-15 months), all as routine prophylaxis (Table 2 ). For 13 (87%) patients, the prescribed infusion frequency was lower than for their previous regimen. Eight (53%) patients were prescribed a 50 IU kg BIW regimen, consistent with the product label. 9 Four patients (three children and one adult) received a higher dose regimen (60 IU kg twice weekly, 60 IU kg every 3 days, 50 IU kg every 3 days and 75 IU kg three times weekly). In three of these patients, FVIII levels at approximately 72 hours after the initial infusion were ≤1.9%. In a fourth patient, in whom PK assessment was not performed, the presence of target joints informed the dosing decision. Three patients received a reduced dosing intensity regimen compared to that indicated on the product label (50 IU kg every 5-7 days, 50 IU kg every 4 days and 40 IU kg every 3 days). In the one patient whose dose was markedly lower (50 IU kg every 5-7 days), PK assessment showed a FVIII level of 7% on day 7.
Weekly factor consumption after switching to Adynovate was reduced in nine (60%) patients and increased in four (27%) patients; in two (13%) patients, there was no difference in weekly factor consumption. Overall weekly factor consumption decreased by 19% (Table 2) . Based on the limited data available and short follow-up time, it was not possible to assess change in adherence to the prescribed regimen. The estimated difference in weekly cost of factor (wholesale acquisition cost [WAC] , http://www.wolterskluwercdi.com/price-rx/, data on file) revealed an increase of 8% for the cohort as a whole, and just 4% for the 11 patients switching from Advate (Table S1 ).
| Bleeding outcomes during treatment with Adynovate
Among the 15 patients in our cohort, six had no bleeds in the prior 6 months. Nine patients experienced between one and seven (median two) bleeds, of which four had joint bleeds (range 1-6, median two bleeds) ( Table 1 ). Other bleed types included soft-tissue (six bleeds), intramuscular (five) and epistaxis (two). During 1-13 (median 6) months of follow-up after switching to Adynovate prophylaxis, eight patients had no bleeds (Table 2) . Seven patients experienced between one and five (median one) bleeds, of which three had joint bleeds (one, one, and five bleeds, respectively). Other bleeding included bruising (four bleeds), haematuria (two episodes), a traumatic bleed (basketball-related) and extended bleeding from the port site in one patient.
Of note, adults who switched to Adynovate had a greater degree of benefit compared with children ( following the switch (14 bleeds, including mild bruising), compared with five who had a total of 12 bleeds previously. All three haemarthroses following the switch to Adynovate occurred in children, two of whom had also experienced significant joint bleeding prior to the switch. In contrast, a notable positive outcome in a paediatric patient was Case 1, the infant who had persistent gastrointestinal bleeding prior to the switch, but who had only traumatic bruising during treatment with Adynovate.
| Safety/tolerability and immunogenicity of treatment with Adynovate
No patient had an adverse event that was considered to be related to treatment with Adynovate. One patient had two episodes of haematuria related to kidney stones and developed appendicitis. In contrast, two patients/families were not satisfied with treatment with Adynovate. In one case, the parent of a young toddler who had experienced mild but extended bleeding at the existing port site and increased bruising requested a switch back to Advate (Case 2). In another case (Case 8), an adolescent patient and his parent expressed disappointment that while on Adynovate the bleed rate had not improved and that the infusion frequency could not be further reduced.
They decided to switch back to Advate, and subsequently requested to switch to KOVALTRY ® (Bayer, Whippany, NJ, USA).
| Laboratory monitoring of Adynovate
All three haemophilia treatment centres used the one-stage clotting assay to monitor factor VIII levels. As in the pivotal studies, in none of Given the multiplicity of factors involved in personalizing treatment regimens, it is not surprising that the reasons for switching factor therapy were varied. In the patients included in this analysis, switching to Adynovate was most commonly initiated with the goal of reducing infusion frequency or improving bleed control. In the majority of cases, the patient or parent had expressed a preference for switching. In several of these cases, adherence with prophylaxis was suboptimal and the goal was specifically to improve this. In adolescents and young adults as well as children, nonadherence with routine prophylaxis can be an issue and is associated with an increased risk of complications. 18, 19 There were also three cases where the switch was associated with venous access issues.
Frequent venipuncture can be a particular burden for young children, who often require placement of a CVAD, with a risk of infectious and thrombotic complications. 20 Our findings indicate that the goals of treatment switching were met in most patients, and that the burden of treatment was reduced.
Patient or parent-reported benefits included the delay of CVAD placement in an infant, reduced disruption to family life and improved adherence in a young adult (from 50% to >90% adherence). Reports of reduced breakthrough bleeding and improvements in target joints were also noted. Although all patients in our analysis had switched from another prophylactic regimen, the availability of EHL FVIII may facilitate the initiation of prophylaxis in patients who are currently treated on an on-demand basis. 6, 21, 22 At our treatment centres, patients switching to Adynovate are required to attend the clinic for the first infusion. This allows for preinfusion inhibitor testing, pre-and postinfusion FVIII analysis, observation postinfusion for allergic reaction and patient/parent training on product preparation. In our analysis, PK assessment at switching was performed in 10 patients; this typically involved a preinfusion measurement, postinfusion peak measurement and postinfusion measurement at approximately 24, 72 and/or 96 hours. In three patients, no peak measurement was obtained postinfusion. PK assessment contributed to the decision to increase the prophylactic dose above 50 IU kg BIW in three patients, of whom two were children (who typically have higher FVIII clearance 4, 22, 23 ), and to reduce the dose in three patients. In the paediatric pivotal study, less than 10%
of patients required prophylactic dose adjustment. Although PK testing can be challenging as it requires additional visits for phlebotomy, the information is often valuable for individualizing care, improving outcome and/or containing cost. 4, 24, 25 The Phase 3 PROPEL study will help to clarify the role of PK-guided prophylaxis dosing with Adynovate. 26 Follow-up of patients in this analysis was conducted in person or by phone, typically at 1-3 months after the first infusion.
The authors' usual practice would then be to follow up as otherwise scheduled unless there is unexpected bleeding, or to monitor every 3-6 months during the first year only. Typically, patients switched to Adynovate were screened for inhibitors at the next follow-up visit.
A strength of this retrospective chart review study is that the patients were managed at three specialist centres that provide comprehensive haemophilia care with multidisciplinary involvement, resulting in detailed medical records and the opportunity to learn from early adopters of a new therapeutic option. Records of all patients who had initiated Adynovate outside of a clinical study within the prespecified time frame were reviewed, avoiding selection bias. However, the analysis is still limited by the extent and quality of the information available, and by the small number of patients. All but one patient in this study had severe haemophilia, and the one who did not still had significant bleeding symptoms, so these findings cannot be generalized to patients with less severe disease. In addition, all patients were previously treated; therefore, these findings cannot be extrapolated to previously untreated patients. A Phase 3 study assessing the safety, immunogenicity and haemostatic efficacy of Adynovate in previously untreated and minimally treated patients with severe haemophilia A, aged <6 years, is underway. 
